Zeev Bronfeld - 07 Sep 2022 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Reporting relationship: Director
Issuer ticker: PLX
Reported as of: 07 Sep 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Sep 2022, 17:01:49 UTC
Source filing: View source filing
Reporting owner signature: /s/ Eyal Rubin, POA

Key filing fact

Zeev Bronfeld filed Form 4 for Protalix BioTherapeutics, Inc. (PLX) on 09 Sep 2022.

Key facts

This page summarizes Zeev Bronfeld's Form 4 filing for Protalix BioTherapeutics, Inc. (PLX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Sep 2022, 17:01.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLX transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 07 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $1.03
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended, or if the Reporting Person ends his tenure on the Board of Directors within 12 months of the date of grant.

Footnote F2

Does not include options to purchase 240,000 shares of common stock at an exercise price equal to $3.70 per share that expire on February 3, 2030.